Document is current

Article History

Received: 8 March 2018

Accepted: 20 June 2018

First Online: 13 July 2018

Ethics approval and consent to participate

: The study was based on the guidelines for evaluating the target animal safety of new pharmaceuticals (VICH Guideline 43), and to recognized quality assurance standards (United States Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations, 21 Code of Federal Regulations (CFR) Part 58 and the Organization for Economic Cooperation and Development (OECD) Series on Principles of Good Laboratory Practice and Compliance Monitoring, Number 13) [CitationRef removed–CitationRef removed]. The study protocol was reviewed and approved by the study site Ethics Committee (MPI Research, Institutional Animal Care & Use Committee, No 382-218, 02 January 2015) and the sponsor company’s Institutional Animal Care and Use Committee. This manuscript was prepared in compliance with the ARRIVE Guidelines Checklist for animal in vivo experiments [CitationRef removed].

: Not applicable.

: EAK and SK are employees of Elanco Animal Health.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.